Drug Profile
LY 2608204
Alternative Names: LY-2608204Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Singapore (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in South Africa (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO, Capsule)